<DOC>
	<DOCNO>NCT01512056</DOCNO>
	<brief_summary>The purpose study evaluate antibody response dialysis patent three influenza vaccine strain include licensed seasonal flu vaccine ( Formulation 2011-2012 ) .</brief_summary>
	<brief_title>Immunogenicity Safety Trivalent Inactivated Influenza Vaccine , Formulation 2011-2012 , Dialysis Patients</brief_title>
	<detailed_description>The immune response influenza vaccine poor dialysis population general population . The investigator want evaluate another booster vaccination improve immune response dialysis population . All enrol participant divide 3 group : participant refuse receive vaccination , receive either one ( week 0 ) one booster vaccination ( week 0 week 3 ) . The investigator collect serum participant 3 week , 6 week , 9 week 18 week post vaccination evaluate difference immune response 3 group .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males nonpregnant female age 18 year ; 2 . Willing able adhere visit schedule study requirement ; 3 . Subjects read sign studyspecific inform consent . 1 . Subject his/her family employ participated hospital ; 2 . Subjects receive 20102011 seasonal influenza vaccine within previous 6 month ; 3 . History hypersensitivity egg egg protein similar pharmacological effect study medication ; 4 . Personal family history GuillainBarré Syndrome ; 5 . An acute febrile illness within 1 week prior vaccination ; 6 . Current upper respiratory illness , include common cold nasal congestion within 72 hour ; 7 . Subjects influenzalike illness define presence fever ( temperature ≥ 38°C ) least two follow four symptom : headache , muscle/joint ache pain ( e.g . myalgia/arthralgia ) , sore throat cough ; 8 . Female subject pregnant study . 9 . Patients receive hemodialysis therapy le 3 month . 10 . Treatment investigational drug device , participation clinical study , within 3 month consent ; 11 . Immunodeficiency , immunosuppressive treatment . 12 . Receipt vaccine within 1 week prior study vaccination expect receipt Visit 1 ( study vaccination ) Visit 2 ( final collection blood sample ) ; 13 . Receipt blood product , include immunoglobulin prior 3 month ; 14 . Any severe illness need hospitalization within three month . 15 . Underlying condition investigator ' opinion may interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>dialysis</keyword>
	<keyword>vaccine</keyword>
	<keyword>Seroprotection</keyword>
	<keyword>Seroresponse</keyword>
	<keyword>Seroconversion</keyword>
	<keyword>Safety vaccine</keyword>
</DOC>